Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-09-18 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于实际控制人和董事收到行政处罚事先告知书的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding administrative penalties received by the actual controller and a director of the company related to information disclosure violations by another company. It includes details of fines and market bans but explicitly states that the violations are unrelated to the company itself. The document is short (770 characters) and serves as a regulatory disclosure about legal proceedings involving company insiders. It does not contain financial data, management discussion, or report publication information. Therefore, it fits best under Legal Proceedings Report (LTR).
2024-09-18 Chinese
江苏四环生物股份有限公司关于全资子公司签署《搬迁补偿协议书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Sihuan Bio Co., Ltd. regarding a compensation agreement signed by its wholly-owned subsidiary for tree relocation fees related to a construction project. It details the agreement terms, payment schedule, and expected accounting treatment. There is no financial report, earnings data, or regulatory certification. The document is a corporate announcement about a specific operational event affecting the company, not a financial report or regulatory filing. It fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-13 Chinese
江苏四环生物股份有限公司关于实际控制人部分股份被轮候冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the freezing of shares held by the actual controller of the company, including detailed tables of frozen shares and related legal circumstances. It does not contain financial statements, management discussion, or detailed financial results. It is a regulatory announcement about shareholding restrictions and legal actions affecting shares, which fits the category of Regulatory Filings (RNS) as it is a compliance disclosure related to shareholder status and legal matters, not a financial report or voting result.
2024-09-06 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司2024 年半年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2024 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, risk factors, governance information, environmental and social responsibility, and a full set of financial statements. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial figures for the half-year period of 2024, management analysis, and detailed notes, which are characteristic of an Interim / Quarterly Report. The document is not a mere announcement or certification but a full report covering a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-08-30 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a summary table detailing non-operating fund occupation and other related party fund transactions for the period January to June 2024. It includes specific financial figures, accounting subjects, and relationships between parties. The presence of detailed financial data and accounting information for a half-year period indicates this is a financial report related to interim or quarterly reporting. The document length is short (1114 characters), but it contains substantive financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-30 Chinese
江苏四环生物股份有限公司舆情应对制度
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" which translates to "Public Opinion Management System" or "Crisis Management Policy" for Jiangsu Sihuan Bioengineering Co., Ltd. It outlines the company's internal procedures and responsibilities for managing public opinion, media reports, and potential crises affecting the company’s stock price and reputation. There are no financial statements, no mention of fiscal periods, no audit information, no voting results, no earnings data, no capital or financing updates, no legal proceedings, no merger or acquisition details, and no regulatory filings or announcements of reports. The document is a governance-related internal policy document detailing organizational structure, responsibilities, and procedures for managing public relations and crisis communications. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3081 characters, which is not extremely short, and it is not an announcement but a full policy document. Hence, the classification is CGR with high confidence.
2024-08-30 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.